Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
March 14, 2005
- NEW PRODUCTS
March 14, 2005
- 3M Pharm, Takeda to Collaborate on Treatment for HPV Infection
March 14, 2005
- Takeda Obtains Candesartan Add. Indication for Heart Failure
March 14, 2005
- DIA Workshop on Clinical Trials Discusses AE Reporting
March 14, 2005
- Execommunications to Acquire Kobashou's Subsidiary Kics
March 14, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 14, 2005
- Nippon Shinyaku Forecasts 2.1% Growth in Sales for FY2004
March 14, 2005
- PRESS SEMINAR
March 14, 2005
- Mochida's R&D to Focus on Lifestyle Diseases, Chronic Pain
March 14, 2005
- OTC NEWS IN BRIEF
March 14, 2005
- VIWES & OPINIONS
March 14, 2005
- MEDICAL DEVICE NEWS IN BRIEF
March 14, 2005
- Aiming for \1 Tril. in Sales in FY2011: Mr Naito of Eisai
March 14, 2005
- Sales of Pfizer Japan Increase 25.2% to \385.6 Bil.
March 14, 2005
- Committee Recommends Approval of In Vivo Diagnostic Adenosine
March 14, 2005
- Japan Pharmaceutical Roundtable-Economist Conference
March 14, 2005
- 5 Drugs Including Vfend Recommended for Approval
March 14, 2005
- BUSINESS NEWS IN BRIEF
March 14, 2005
- Interstitial Pneumonia Due to Arava Evaluated: Safety Inf. No. 201
March 14, 2005
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…